The overall goal of the University of lowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE) Administration Core is to stimulate research in lymphoma and to expedite the translafion of discoveries into new and better methods of prevenfion, detecfion, and treatment of lymphoma. The Administration Core has served well as the organizational hub of UI/MC SPORE during the prior funding periods. During the next grant period (years 11-15), it will continue to provide an organizafional structure designed to coordinate the activifies ofthe research projects, scientific ceres, and developmental programs (Developmental Research Program, Career Development Program) at both institutions. The Administrafion Core will be responsible fer coordinating the function of the SPORE committees including the Executive Committee and the External Advisory Committee, Dr. George Weiner will serve as Director of the Administrafion Core, and Dr. Thomas Witzig as Co- Director. Weiner and Witzig functioned well as a team during the prior funding periods, and will confinue to work collaboratively to provide oversight of SPORE activities. The Administration Core will 1) Provide leadership, organizafional support, and financial management fer UI/MC SPORE invesfigators; 2) Coordinate communication and collaborafion between lowa and Mayo, including support for exchange of ideas between investigators, design of new projects, conduct of translational research, and reporting of translational research findings; 3) Provide informafion transfer to the scientific community and the public; 4) Provide leadership and organizafional supportfor internal and external review for UI/MC SPORE research projects; 5) Provide the structure for the establishment and nurture of collaborafions to facilitate and expand lymphoma research including interactions between lowa and Mayo; 6) Work closely with SPORE pafient advocates se that they are aware of the progress of the SPORE, and facilitate their ability to provide input at all levels; 7) Foster trainee development; 8) Communicate with the NCI.

Public Health Relevance

The Administration Cere provides administrative support for all UI/MC SPORE research activifies and assures there is excellent communication between lowa and Mayo, and all participafing investigators and staff. The Administration Core also assures that patient advocates participate in videoconferences and annual retreats and are included in all key decisions. It is a necessary component for a successful SPORE

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA097274-11S1
Application #
8561356
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
2002-09-20
Project End
2017-06-30
Budget Start
2012-09-12
Budget End
2013-06-30
Support Year
11
Fiscal Year
2012
Total Cost
$10,064
Indirect Cost
$3,399
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Link, Brian K (2017) Early Relapse in Follicular Lymphoma: High Risks and High Stakes. J Oncol Pract 13:810-811
Ding, Wei; LaPlant, Betsy R; Call, Timothy G et al. (2017) Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 129:3419-3427
Ammann, Eric M; Shanafelt, Tait D; Larson, Melissa C et al. (2017) Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clin Lymphoma Myeloma Leuk 17:e11-e25
Wafa, Emad I; Geary, Sean M; Goodman, Jonathan T et al. (2017) The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response. Acta Biomater 50:417-427
Paulus, A; Akhtar, S; Yousaf, H et al. (2017) Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 7:e565
Tanaka, Yoshimasa; Iwasaki, Masashi; Murata-Hirai, Kaoru et al. (2017) Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug. Sci Rep 7:5987
Wang, Xueju; Dasari, Surendra; Nowakowski, Grzegorz S et al. (2017) Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. Oncotarget 8:26245-26255
Scott, David W; Abrisqueta, Pau; Wright, George W et al. (2017) New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. J Clin Oncol 35:1668-1677
Tracy, S I; Maurer, M J; Witzig, T E et al. (2017) Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. Blood Cancer J 7:e595
Law, Philip J; Berndt, Sonja I; Speedy, Helen E et al. (2017) Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nat Commun 8:14175

Showing the most recent 10 out of 337 publications